Cover Image
市場調查報告書

阿霉素市場分析:各用途 (卵巢癌、多發性骨髓瘤、卡波西氏肉瘤、白血病、骨癌、乳癌、子宮內膜癌、胃癌、肝癌症、腎癌症、其他癌症)的市場區隔預測

Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024

出版商 Grand View Research, Inc. 商品編碼 408950
出版日期 內容資訊 英文 84 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
阿霉素市場分析:各用途 (卵巢癌、多發性骨髓瘤、卡波西氏肉瘤、白血病、骨癌、乳癌、子宮內膜癌、胃癌、肝癌症、腎癌症、其他癌症)的市場區隔預測 Doxorubicin Market By Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, Other Cancers) And Segment Forecasts, 2013 - 2024
出版日期: 2016年11月23日 內容資訊: 英文 84 Pages
簡介

本報告提供全球阿霉素市場相關調查,市場趨勢,各用途,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 調查方法

第2章 摘要整理

第3章 市場變動,趨勢,範圍

  • 市場區隔
    • 促進要素分析
    • 阻礙要素分析
  • 滲透、成長預測製圖
  • SWOT分析
  • 產業分析:波特

第4章 各用途預測、趨勢分析

  • 各用途趨勢分析
  • 卡波西氏肉瘤
  • 白血病
  • 骨癌
  • 乳癌
  • 子宮內膜癌
  • 胃癌
  • 肝癌症
  • 腎癌症
  • 其他癌症

第5章 各地區預測、趨勢分析

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第6章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-288-4

The global doxorubicin market was valued at USD 0.81 billion in 2015 and is expected to reach a value of USD 1.38 billion by 2024, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below.

  • Leukemia: 60,140
  • Breast cancer: 2,46,660
  • Endometrial cancer: 60,050
  • Gastric cancer: 26,370
  • Liver cancer: 39,230
  • Kidney Cancer: 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Further Key Findings from the Study Suggest:

  • In 2015, breast cancer is the largest application of doxorubicin market, having a share of around 21.1%. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
  • Liver cancer segment is the fastest growing application in this sector. The growing demand for the drug in combination and mono chemotherapies to treat liver cancer over other anticancer drugs is one of the crucial factors that is expected to boost the industry growth.
  • In 2015, North America held majority of market share of over 48.8% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
  • Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.
  • Some of the key market players are Sun Pharmaceutical Industries Ltd., Pfizer, Inc., Cipla, Inc., Cadila Pharmaceuticals, and SRS Pharmaceuticals Pvt. Ltd.

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Increasing number of market players
      • 3.1.1.2 Increasing application of doxorubicin
      • 3.1.1.3 Growing number of cancer cases
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Supply demand gap
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Doxorubicin Market- SWOT Analysis, by Factor (Political &Legal, Economic, and Technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Market Categorization 1: Application Estimates & Trend Analysis

  • 4.1 Doxorubicin Market: ApplicationMovement Analysis
  • 4.2 Ovarian Cancer
    • 4.2.1 Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.3 Multiple Myeloma
    • 4.3.1 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.4 Kaposi Sarcoma
    • 4.4.1 Kaposi Sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.5 Leukemia
    • 4.5.1 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.6 Bone sarcoma
    • 4.6.1 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.7 Breast cancer
    • 4.7.1 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.8 Endometrial cancer
    • 4.8.1 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.9 Gastric cancer
    • 4.9.1 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.10 Liver cancer
    • 4.10.1 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.11 Kidney cancer
    • 4.11.1 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • 4.12 Other cancer
    • 4.12.1 Other cancer market estimates and forecasts, 2013 - 2024 (USD Million)

Chapter 5 Market Categorization 4: Regional Estimates & Trend Analysis

  • 5.1 Doxorubicin Market Share by Region, 2013 & 2024
  • 5.2 North America
    • 5.2.1 North America doxorubicin market estimates and forecasts, by application 2013 - 2024(USD Million)
    • 5.2.2 U.S.
      • 5.2.2.1 U.S. doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.2.3 Canada
      • 5.2.3.1 Canada doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
  • 5.3 Europe
    • 5.3.1 Europe doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.3.2 Germany
      • 5.3.2.1 Germany doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.3.3 UK
      • 5.3.3.1 UK doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.4.2 Japan
      • 5.4.2.1 Japan doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 China doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Latin America doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.5.2 Brazil
      • 5.5.2.1 Brazil doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.5.3 Mexico
      • 5.5.3.1 Mexico doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
  • 5.6 MEA
    • 5.6.1 MEA doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)
    • 5.6.2 South Africa
      • 5.6.2.1 South Africa doxorubicin market estimates and forecasts, by application 2013 - 2024 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Strategy Framework
  • 6.2 Market Participation Categorization
  • 6.3 Company Profiles
    • 6.3.1 Pfizer, Inc.
      • 6.3.1.1 Company overview
      • 6.3.1.2 Financial performance
      • 6.3.1.3 Product benchmarking
      • 6.3.1.4 Strategic initiatives
    • 6.3.2 Sun Pharmaceutical Industries Ltd.
      • 6.3.2.1 Company overview
      • 6.3.2.2 Financial performance
      • 6.3.2.3 Product benchmarking
      • 6.3.2.4 Strategic initiatives
    • 6.3.3 Cipla, Inc.
      • 6.3.3.1 Company overview
      • 6.3.3.2 Financial performance
      • 6.3.3.3 Product benchmarking
      • 6.3.3.4 Strategic initiatives
    • 6.3.4 Cadila Pharmaceuticals
      • 6.3.4.1 Company overview
      • 6.3.4.2 Financial performance
      • 6.3.4.3 Product benchmarking
      • 6.3.4.4 Strategic initiatives
    • 6.3.5 SRS PHARMACEUTICALS PVT. LTD.
      • 6.3.5.1 Company overview
      • 6.3.5.2 Financial performance
      • 6.3.5.3 Product benchmarking
      • 6.3.5.4 Strategic initiatives
    • 6.3.6 Janssen Products, LP
      • 6.3.6.1 Company overview
      • 6.3.6.2 Financial performance
      • 6.3.6.3 Product benchmarking
      • 6.3.6.4 Strategic initiatives

List of Tables

  • Table 1 Approved doxorubicin products, by approval date and company name
  • Table 2 Estimated number of cancer cases and deaths, by type in 2016
  • Table 3 Cancer Prevalence, by type and region in 2012
  • Table 4 Number of patients treated using doxorubicin, 2012
  • Table 5 North America doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 6 Estimated new cases of cancer, by type and age, 2015
  • Table 7 U.S. doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 8 Canada doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 9 Europe doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 10 UK doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 11 Germany doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 12 Asia Pacific doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 13 Number of cancer cases by site in 2015
  • Table 14 Japan doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 15 China doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 16 Latin America doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 17 Brazil doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 18 Mexico doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 19 MEA doxorubicin market, by application, 2013 - 2024 (USD Million)
  • Table 20 South Africa doxorubicin market, by application, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT analysis, by factor (Political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 Doxorubicin Market: Application outlook key takeaways
  • FIG. 10 Doxorubicin Market: Application movement analysis
  • FIG. 11 Ovarian market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 12 Multiple myeloma market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 13 Kaposi sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 14 Leukemia market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 15 Bone sarcoma market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 16 Breast cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 17 Endometrial cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 18 Gastric cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 19 Liver cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 20 Kidney cancer market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 21 Other cancer application market estimates and forecasts, 2013 - 2024 (USD Million)
  • FIG. 22 Regional market place: Key takeaways
  • FIG. 23 Regional outlook, 2015 & 2024
  • FIG. 24 North America doxorubicin market estimates and forecasts,by application, 2013-2024(USD Million)
  • FIG. 25 U.S. doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
  • FIG. 26 Canada doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
  • FIG. 27 Europe doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
  • FIG. 28 Germany doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
  • FIG. 29 UK doxorubicin market estimates and forecasts, by application, 2013-2024(USD Million)
  • FIG. 30 Asia Pacific doxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
  • FIG. 31 Japan doxorubicin market estimates and forecasts, by application, 2013- 2024(USD Million)
  • FIG. 32 Chinadoxorubicin market estimates and forecasts, by application, 2013 - 2024(USD Million)
  • FIG. 33 Latin America doxorubicin market estimates and forecasts, by application, 2013-2024 (USD Million)
  • FIG. 34 Brazildoxorubicin market estimates and forecasts, by application, 2013 - 2024 (USD Million)
  • FIG. 35 Mexico doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
  • FIG. 36 MEA doxorubicin market estimates and forecasts,by application 2013-2024(USD Million)
  • FIG. 37 South Africa doxorubicin market estimates and forecasts,by application, 2013 - 2024(USD Million)
  • FIG. 38 Strategy framework
  • FIG. 39 Participant categorization
Back to Top